OVERVIEW
DOCUMENTS/REFERENCES
Biological Information
Background Information:
Metabolic profiling of therapeutic compounds at early stages in the drug discovery process is of increasing importance. Drugs that undergo metabolism in vivo may produce pharmacologically-active or chemically reactive metabolites which can produce unexpected effects or potential toxicities. The recent FDA Guidance for Industry on Safety Testing of Drug Metabolites highlights the relevance of in vitro metabolite profiling early in drug development, as metabolites which are unique to or disproportionate in humans may require additional toxicological studies. In addition to the extensive panel of in vitro metabolism screening assays, Eurofins is able to perform studies using state-of-the-art MS instrumentation to thoroughly characterize the metabolic products of a drug compound in vivo or in vitro and compare metabolic profiles across species.
Organism:
Mouse
Construct Details:
Microsomes
Tissue:
Liver
Assay Information
Assay Type:
Biochemical
Assay Sub Type:
Enzymatic
Detection Method:
HPLC-MS/MS
Platform:
Xevo® G2 QTof
Measured Response:
Peak Area Response
Testing Information
Substrate:
Test compound
Test Sample Requirements:
Minimum for 1) Screen: 100 μl of 10 mM stock -OR- 1 to 2 mg (pre-weighed). 2) Dose Response: 250 μl of 10 mM stock -OR- 1.5 to 2 mg (pre-weighed).
Turnaround Time
Standard:
15 Business Days
Additional Information
Brand:
Cerep
Testing Location:
USA - St Charles, MO
Other Information:
Client to provide compound chemical structure to Client Services prior to study initiation for Metabolite ID services. If client does not have Intrinsic Clearance data on the requested compound, then the client will need to run Intrinsic Clearance in the corresponding matrix prior to the initiation of the Metabolite ID study.
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
